论文部分内容阅读
目的:观察吉西他滨(健择)联合诺维本方案(GN方案)治疗蒽环类或紫杉类耐药性晚期乳腺癌的疗效与安全性。方法:39例对蒽环类或紫杉类耐药性晚期乳腺癌患者,接受GEM1000mg/m2静滴,第1、8天,NVB25mg/m2,静滴,第1、8天,每21天为1周期,至少应用2周期。以WHO标准评价疗效和毒性。结果:39例患者中,CR2例(5.1%),PR18例(46.2%),SD11例(28.2%),PD8例(20.5%),RR为51.3%。中位缓解期7.9个月(4～23个月)。主要不良反应为骨髓抑制、消化道反应,均为可逆性。结论:GP方案治疗蒽环类或紫杉类耐药性晚期乳腺癌疗效较好,毒性反应可以耐受,是二线治疗蒽环类或紫杉类耐药性晚期乳腺癌的有效解救方案。
Objective: To observe the efficacy and safety of gemcitabine combined with novibenzide regimen (GN regimen) in the treatment of anthracycline-resistant or taxane-resistant advanced breast cancer. Methods: Thirty-nine patients with anthracycline or taxane-resistant advanced breast cancer were treated with GEM1000mg / m2 iv, day1, day8, NVB25mg / m2, intravenous drip, 1 cycle, at least 2 cycles apply. To evaluate the efficacy and toxicity of WHO standards. Results: Of 39 patients, CR2 (5.1%), PR18 (46.2%), SD11 (28.2%), PD8 (20.5%) and RR 51.3%. The median remission was 7.9 months (4-23 months). The main adverse reactions are myelosuppression, gastrointestinal reactions, are reversible. Conclusions: GP regimen is effective in treating anthracycline or taxane-resistant advanced breast cancer and its toxicity can be tolerated. It is an effective rescue plan for second-line treatment of advanced breast cancer with anthracyclines or taxanes.